Qure.ai Reviews

Qure.ai Technologies is a prominent global healthcare technology company specializing in artificial intelligence and deep learning solutions for medical imaging analysis. Founded in July 2016 by Prashant Warier and Pooja Rao, the company is headquartered in Mumbai, India, with additional corporate offices in Bengaluru, New York City, London, and the UAE. Qure.ai was incubated within the data analytics firm Fractal Analytics and operates with a mission to make healthcare more accessible, affordable, and equitable for patients worldwide by providing automated, timely assistance to healthcare professionals. The core operations of Qure.ai center on developing advanced, hardware-agnostic algorithms capable of interpreting radiology scans within seconds. Its flagship product, qXR, is an AI-based chest X-ray interpretation tool that identifies and localizes over 35 conditions, including tuberculosis (TB), lung cancer, and heart failure. Trained on a dataset of over 9 million scans, qXR automates critical aspects of the diagnostic process, enabling decentralized decision-making at primary healthcare centers. Additionally, the company offers qER, a monitoring tool for automated interpretation and triage of critical findings on head CT scans, capable of detecting intracranial hemorrhages, cranial fractures, and midline shifts. Its qQuant suite provides automated detection, quantification, and 3D visualization for CT and MRI scans, which is utilized in evaluating pharmaceutical clinical trial outcomes. Qure.ai's solutions are backed by rigorous scientific evidence, featuring in over 121 publications and holding 13 patents. The company has achieved significant regulatory milestones, including multiple FDA clearances and CE certifications. Notably, its chest X-ray solution received a World Health Organization (WHO) endorsement for TB screening in settings without human readers. Qure.ai operates across more than 3,100 sites in over 90 to 100 countries, impacting more than 45 million lives globally across regions such as APAC, Africa, Europe, the Middle East, and Latin America. Financially, Qure.ai is a venture-backed, later-stage private entity. The company has raised approximately $130 million to $156 million in total capital across nine funding rounds. Its prominent institutional investors include Sequoia Capital India (now Peak XV Partners), MassMutual Ventures, Lightspeed India Partners, Merck Global Health Innovation Fund, HealthQuad, and Kae Capital. In January 2026, the company received a grant from the Bill & Melinda Gates Foundation to build an open-source lung health database. Qure.ai is led by Co-Founder and CEO Prashant Warier, alongside a leadership team that includes Chief Strategy & Growth Officer Ankit Modi and Chief Financial Officer Harsh Vaish. The company actively collaborates with global organizations like the Stop TB Partnership, PATH, and AstraZeneca to advance low-carbon, scalable health screening infrastructure.